EKF Diagnostics Investor Announcements
EKF Diagnostics Holdings plc is an in-vitro diagnostics (IVD) business. The Company is engaged in the designing, development, manufacture and selling of diagnostic analyzers, reagents and ancillary products. This activity takes place across several geographical locations which include the United Kingdom, United States of America, Germany, Poland and Russia.
EKF Diagnostics announces that the Board of Directors have initiated a strategic review.
Audited final results for the year ended 31 December 2014.
EKF Diagnostics subsidiary , Selah Genomics, has announced a major, four-way collaboration with Greenville Health System (GHS, North Carolina), DecisionQ Corporation (Washington DC), and BD Technologies (New Jersey).
Major 18 month collaboration in the US using PrecisionPath to provide genetic profiles of cancer tumours.
EKF Diagnostics Holdings plc will announce its preliminary results.
EKF Diagnostics, announces that it has introduced a new diabetic biomarker test that provides a 2-3 week indicator of average blood glucose.
EKF announces the appointment of Panmure Gordon (UK) Limited as its Nominated Adviser and Broker.